Absci (ABSI) Expected to Announce Quarterly Earnings on Thursday

Absci (NASDAQ:ABSI) is projected to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.4140 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Absci (NASDAQ:ABSI) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%.The business had revenue of $0.65 million during the quarter, compared to the consensus estimate of $1.38 million. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of Absci stock traded down $0.05 during trading hours on Tuesday, reaching $5.58. The company’s stock had a trading volume of 2,285,556 shares, compared to its average volume of 3,942,043. The company’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $3.29. Absci has a one year low of $2.24 and a one year high of $5.75. The stock has a market cap of $866.63 million, a P/E ratio of -6.58 and a beta of 2.36.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ABSI. Needham & Company LLC restated a “buy” rating and issued a $7.00 price target on shares of Absci in a research report on Wednesday, March 25th. Morgan Stanley downgraded shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target on the stock. in a research report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $6.44.

Insiders Place Their Bets

In other news, insider Andreas Busch acquired 100,000 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were purchased at an average cost of $2.29 per share, for a total transaction of $229,000.00. Following the transaction, the insider directly owned 421,446 shares in the company, valued at $965,111.34. This trade represents a 31.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Absci

Several hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its position in Absci by 14.3% in the 4th quarter. Invesco Ltd. now owns 54,550 shares of the company’s stock valued at $190,000 after purchasing an additional 6,826 shares during the last quarter. XTX Topco Ltd lifted its position in Absci by 380.9% in the 4th quarter. XTX Topco Ltd now owns 136,874 shares of the company’s stock valued at $478,000 after purchasing an additional 108,413 shares during the last quarter. Wellington Management Group LLP increased its stake in Absci by 8.5% during the 4th quarter. Wellington Management Group LLP now owns 410,124 shares of the company’s stock valued at $1,431,000 after buying an additional 32,267 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Absci during the 4th quarter valued at about $8,201,000. Finally, Abel Hall LLC acquired a new position in Absci during the 4th quarter valued at about $54,000. 52.05% of the stock is currently owned by institutional investors.

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.